Moomoo Releases Redesigned Desktop Platform

JERSEY CITY, N.J., Oct. 18, 2024 — Moomoo has recently launched its redesigned desktop platform to better serve U.S. retail investors and help them unlock their trading potential. The newly developed, client-driven platform provides customizable multi-monitor layouts with advanced features specifically tailored for investors, including powerful charting and analytical tools.…

MicuRx Pharmaceuticals Highlights Pipeline Progress for MRX-5 and MRX-8 at BIO Investor Forum

SAN FRANCISCO, Oct. 18, 2024 — Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of the company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the future treatment of Nontuberculous Mycobacterial (NTM) pulmonary diseases and Pseudomonas…

Accord Healthcare’s Biosimilar to Stelara® Receives Positive CHMP Opinion

Accord announces that the CHMP has issued a positive opinion for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immunology conditions. The approval of Imuldosa® further enhances Accord Healthcare’s biosimilar portfolio and strengthens Accord’s Autoimmune Franchise building on existing leading brands. Imuldosa® will be the 5th biosimilar for…

Foreign Journalists and Bloggers Explore the “Pearl of Western Jiangxi”

PINGXIANG, China, Oct. 19, 2024 — A report from Jiangxi International Communication Center(JXICC): Recently, a group of foreign journalists and bloggers from seven countries including the UK, Japan, South Korea, and Indonesia visited Pingxiang in Jiangxi Province. They explored Pingxiang's cultural heritage and witnessed the stunning natural beauty of Wugong Mountain. Pingxiang,…